Latest Biotechnology News

Page 46 of 71
Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.
Ada Torres
Ada Torres
29 July 2025
Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.
Ada Torres
Ada Torres
29 July 2025
Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.
Ada Torres
Ada Torres
29 July 2025
Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.
Ada Torres
Ada Torres
29 July 2025
Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.
Ada Torres
Ada Torres
29 July 2025
Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.
Ada Torres
Ada Torres
29 July 2025
Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.
Ada Torres
Ada Torres
28 July 2025
Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.
Ada Torres
Ada Torres
28 July 2025
Alterity Therapeutics has reported encouraging topline results from its open-label Phase 2 trial of ATH434 in advanced Multiple System Atrophy, showing slowed disease progression and biomarker stabilization.
Ada Torres
Ada Torres
28 July 2025
Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.
Ada Torres
Ada Torres
28 July 2025
Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.
Ada Torres
Ada Torres
28 July 2025
NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.
Ada Torres
Ada Torres
28 July 2025